Marché allemand du syndrome de stress post-traumatique (SSPT) – Tendances et prévisions du secteur jusqu’en 2030

Analyse et perspectives du marché allemand du syndrome de stress post-traumatique (SSPT)

Le trouble de stress post-traumatique (TSPT) est un trouble de santé mentale déclenché par un événement terrifiant, que l’on ait vécu ou dont on ait été témoin. Les symptômes peuvent inclure des flashbacks, des cauchemars et une anxiété sévère, ainsi que des pensées incontrôlables sur l’événement. La plupart des personnes qui vivent des événements traumatisants peuvent avoir des difficultés temporaires à s’adapter et à faire face, mais avec le temps et de bons soins personnels, elles s’améliorent généralement. Si les symptômes s’aggravent et durent des mois, voire des années, et interfèrent avec le fonctionnement quotidien, on parle alors de TSPT. Obtenir un traitement efficace après l’apparition des symptômes du TSPT peut être essentiel pour réduire les symptômes et améliorer le fonctionnement.

Le marché allemand du trouble de stress post-traumatique (TSPT) devrait croître au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 4,4 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 210,44 millions USD d'ici 2030.

Définition du marché du syndrome de stress post-traumatique (SSPT) en Allemagne

Le trouble de stress post-traumatique (TSPT) est un trouble qui se développe chez certaines personnes qui ont vécu un événement choquant, effrayant ou dangereux.

It is the complex somatic, cognitive, affective, and behavioral effects of psychological trauma. It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.

Post-traumatic stress disorder (PTSD) treatment help to improve patients thinking power, changes in physical activity & regain a sense of control over life. The mode of treatment applied for post-traumatic stress disorder includes medication, therapies, self-care & nutrition.

The rising prevalence of Post-traumatic stress disorder (PTSD) and technological advancements in diagnosis and treatment of PTSD in recent years is boosting the market growth while high treatment cost and adverse effects associated with treatment are working as restrain for the Germany Post-Traumatic Stress Disorder (PTSD) Market.

Germany Post-Traumatic Stress Disorder (PTSD) Market Dynamics

Drivers

Rising prevalence of PTSD.

Post-Traumatic Stress Disorder (PTSD) is a complex physical, cognitive, emotional, and behavioral consequence of psychological trauma. It is characterized by intrusive thoughts, nightmares, and flashbacks to past traumatic events, avoidance of traumatic reminders, hypervigilance, and sleep disturbance, all of which contribute to significant social, occupational, and interpersonal dysfunction.

PTSD is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape, or who have been threatened with death, sexual violence, or serious injury.

As a result, an increasing number of PTSD cases every year calls for the need for improved diagnostic processes and techniques for the treatment of PTSD patients.

Thus, due to a rising prevalence of PTSD, it is expected to act as a driving factor for market growth.

Technological advancements in the diagnosis and treatment of PTSD.

Various technologies, including heart rate monitors, electroencephalography (EEG), audio recorders, and eye-tracking peripherals, are now being used to capture and analyze neurological and physiological data to identify markers for the condition of PTSD.

Video conferencing is emerging as a viable method for providing psychiatric care and individual and group-based trauma interventions within underserved and geographically remote populations. Exposure therapy is an effective treatment for PTSD. Exposure therapy is another type of therapy that decreases PTSD symptoms through imaginal exposure (i.e., vividly imaging the feared object, situation, or activity) aimed at helping individuals overcome, rather than avoid, fear- and psychological distress-inducing stimuli.

The increasing incidence of PTSD

PTSD is a clinically diagnosed condition that occurs in about 20% of all individuals who experience or witness a traumatic event that involves the actual or possible threat of death, violence, or serious injury. Examples of traumatic events include experiencing or witnessing a natural disaster, serious accident, terrorist act, war/combat, rape, or being threatened with death, sexual violence, or serious injury.

The increase in the number of incidences every year is thus encouraging manufacturers' government officials to introduce innovative diagnostic techniques, which is expected to boost the market growth in upcoming years.

Hence, the rising number of new incidences of PTSD every year is expected to act as a driver for the market's growth.

Increased awareness among patients and doctors regarding therapies for PTSD

Increased awareness leads to an increase in the treatments and diagnoses of the patients. At the same time, early detection of PTSD will help therapists who are specialized in PTSD to ensure a good recovery. Many people with PTSD often deal with negative thoughts and feelings, which can greatly affect their emotional health and well-being. Many people with PTSD may feel a sense of guilt or responsibility for their trauma. Thus, increasing awareness of PTSD helps patients to get the right treatment.

Hence, the increased awareness among patients and doctors regarding therapies for PTSD is expected to act as a driver for the growth of the market.

Restraints

High cost of the treatment

Post-traumatic stress disorders (PTSD) pose a high burden for individuals and societies. Although prevalence rates are rather low, high co-occurrence rates and overall impairments cause deleterious suffering and significant treatment costs. The cost of treating PTSD can vary significantly. Some patients can get very low-cost care from the government, but many choose to get private care and pay out of pocket, which can easily add up to thousands in a year.

Thus, the high cost of treatment will is expected to act as a major restraining factor for the growth of the market.

Side effects associated with PTSD treatment

There are several types of antidepressant drugs that can be used to treat PTSD, Antidepressants have several side effects. They vary depending on the medication and affect people differently. The most common side effects include: dry mouth, nausea, constipation, diarrhea, headache, drowsiness, insomnia, high or low blood pressure, light-headedness, sexual difficulties, changes in appetite that can lead to weight gain or loss, excessive sweating—venlafaxine, blurry vision caused by drug nefazodone and severe liver damage caused by drug nefazodone

Risk of severe mood and behavior changes, including suicidal thoughts in some patients (Young adults may be at a higher risk for this side effect.) Hence, the side effects associated with PTSD treatment is expected to hamper the market growth.

Opportunities/Challenges

Rising healthcare expenditure

The expense of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization for the healthcare system. In particular, there is a strong association between the whole income level of a country and how much the country's population spends on its healthcare.

The psychotherapies, or pharmacotherapies, are beneficial for individuals with PTSD, and early preventive approaches could prevent high incremental costs.

The costs are constantly increasing year by year at a small rate, which can be explained by overall increases in healthcare expenditures within the German statutory healthcare system

Growing healthcare expenditure is expected to increase the availability of Post-Traumatic Stress Disorder treatment drugs for better patient treatment with fewer human medical errors. Hence, the massive healthcare expenditure is a favorable factor and is expected to create a significant opportunity for the growth of the Post-Traumatic Stress Disorder market.

Rising approvals of drugs

The rising approvals of drugs for Post-traumatic stress disorder by The Federal Institute for Drugs and Medical Devices (BfArM) and experts contribute their knowledge to the scientific committees of the European Medicines Agency (EMA), among others. Throughout the EU and internationally, BfArM significantly contributes to the supply of safe and effective medicines.

The Federal Institute for Drugs and Medical Devices has increased the approval of drugs to treat post-traumatic stress disorder. These approval received for PTSD drugs would result in the medicine being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of medicines to the developing markets in the Germany region. Hence, the rise in product approvals is expected to propel market growth.

Patent expiry of drugs

Patent expiry of innovator pharmaceutical companies changes the market dynamics that brought the increased production of generics by rival companies after the expiry of the patent of the product, which affects the competitive market price changes, pressures, and changes in sales volumes and profit of multinational innovator pharmaceutical companies

The rising number of generic drugs in the market enhances the challenge among the market players that impacts the revenue of the market by reduction of existing drug prices.

The termination of patents would result in fewer chances of product approval and the rise of generic drugs in the market, which may act as a challenge to the growth of the market.

Recent Developments

• In March 2022, AbbVie and Gedeon Richter Plc. (Richter) announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and included several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA. This collaboration helps the company to expand its business and find new and innovative solutions and discoveries in terms of neurological disorders.

Germany Post-Traumatic Stress Disorder (PTSD) Market

Germany post-traumatic stress disorder (PTSD) market is segmented into type, treatment type, route of administration, age group, end user and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

• Dissociative PTSD
• Uncomplicated PTSD
• Comorbid PTSD
• Others

On the basis of type, the Germany post-traumatic stress disorder (PTSD) market is segmented into dissociative PTSD, uncomplicated PTSD, comorbid PTSD, and others.

Treatment Type

• Medication
  • Psychotherapy
  • Software Devices

On the basis of procedure type, the Germany post-traumatic stress disorder (PTSD) market is segmented into medication, psychotherapy, and software devices.

Route of Administration

• Oral
• Parentral
• Others

On the basis of the route of administration, the Germany post-traumatic stress disorder (PTSD) market is segmented into oral, parenteral, and others.

Age Group

• Children
• Adult
• Geriatrics

On the basis of Age group, the Germany post-traumatic stress disorder (PTSD) market is segmented into children, adults, and geriatrics.

End User

• Hospitals
• Outpatient Clinics
• Mental Health Centers
• Home Healthcare
• Others

On the basis of end-user, the Germany post-traumatic stress disorder (PTSD) market is segmented into hospitals, outpatient clinics, mental health centers, home healthcare, and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

On the basis of the distribution channel, the Germany post-traumatic stress disorder (PTSD) market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

Competitive Landscape and Germany Post-Traumatic Stress Disorder (PTSD) Market Share Analysis

Le paysage concurrentiel du marché allemand du syndrome de stress post-traumatique (SSPT) fournit des détails sur un concurrent. Les détails comprennent un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la stimulation du nerf vague.

Français Certains des principaux acteurs opérant sur le marché allemand du trouble de stress post-traumatique (TSPT) sont AbbVie Inc., Viatris Inc, Pfizer Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Aurobindo Pharma., AstraZeneca, Cipla Inc., Lupin, Accord Healthcare GmbH, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc. et GlaxoSmithKline Group of Companies. Teva Pharmaceutical Industries Ltd., Alkermes. et Novartis AG entre autres.

SKU-69518